GoldenGolden
Advanced Search
Elevation Oncology

Elevation Oncology

Elevation Oncology is an oncology Company.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

June 17, 2021
Elevation Oncology announces the appointment of Joseph Ferra as Chief Financial Officer.
November 2020
Elevation Oncology raises a $65,000,000 series B round from Aisling Capital, BVF Partners, Boxer Capital, Cormorant Asset Management, Driehaus Capital Management, Janus Henderson, Qiming Venture Partners, Samsara BioCapital, Vertex Ventures HC, Vivo Capital and venBio Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Elevation Oncology
June 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for...
June 17, 2021
BioSpace
Elevation Oncology Announces Appointment of Joseph Ferra as Chief Financial Officer - read this article along with other careers information, tips and advice on BioSpace
Elevation Oncology
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
Caris Life Sciences; Elevation Oncology
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision...
Nick Paul
June 7, 2021
FierceBiotech
Elevation Oncology has filed to raise $100 million in an IPO. The money will support development of an anti-HER3 antibody that failed multiple trials at Merrimack Pharmaceuticals before being picked up by Elevation and repositioned as a treatment for solid tumors harboring an NRG1 fusion.
BioSpace
May 18, 2021
BioSpace
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the appointment of R. Michael Carruthers to its Board of Directors and Chair of the Audit Committee.
Elevation Oncology
April 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
AlleyWatch
November 19, 2020
AlleyWatch
The Pulse of New York Tech
FinSMEs
November 19, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.